About AVT
Browse Articles
Authors
Customer Services

Addendum

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies

Marianne Martinello1,*, Margaret Hellard2,3,4, David Shaw5, Kathy Petoumenos1, Tanya Applegate1, Jason Grebely1, Barbara Yeung1, Laurence Maire1, David Iser6, Andrew Lloyd7, Alexander Thompson6, Joe Sasadeusz8, Paul Haber9,10, Gregory J Dore1,11, Gail V Matthews1,11

1Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Australia, Sydney, NSW, Australia
2Centre for Population Health, Burnet Institute, Melbourne, VIC, Australia
3Infectious Diseases Unit, Alfred Hospital, Melbourne, VIC, Australia
4Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, VIC, Australia
5Infectious Diseases Unit, Royal Adelaide Hospital, Adelaide, SA, Australia
6Department of Gastroenterology and Hepatology, St Vincent’s Hospital, Melbourne, VIC, Australia
7Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia
8Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia
9Department of Gastroenterology and Hepatology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
10Faculty of Medicine, University of Sydney, Sydney, NSW, Australia
11Department of Infectious Disease and Immunology, St Vincent’s Hospital, Sydney, NSW, Australia

*Corresponding author e-mail: mmartinello@kirby.unsw.edu.au

Citation: Antiviral Therapy 2016; 21:465
doi: 10.3851/IMP3073

Date accepted: 01 July 2016
Date published online: 10 August 2016

Copyright (c) 2016 International Medical Press, all rights reserved.

The authors would like to report an additional serious adverse event (appendicitis requiring hospitalization) in [1]. The updated paragraph can be found below.

Results

DARE-C I

Safety

Multiple adverse events were documented in all participants with the most common being fatigue (73%) and rash (50%; Additional file 1). Three SAEs were reported: skin cancer (SCC/BCC) requiring hospitalization, axillary abscess requiring hospitalization and appendicitis requiring hospitalization. Adverse events requiring medical intervention, treatment cessation or dose modification occurred in 36% (n=5), with dose reduction of PEG-IFN and RBV in one (7%) and three (21%) individuals, respectively.

Reference

-
1. Martinello M, Hellard M, Shaw D, et al. Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies. Antivir Ther 2016; doi:10.3851/IMP3035.Medline doi:10.3851/IMP3035

Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.